JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma

Table 1

Correlation of JAK3/TYK2 mRNA expression and overall survival in STAD with different clinicopathological factors (Kaplan–Meier plotter).

Pathological parameters	Overall survival
	JAK3			TYK2
		Hazard radio	value		Hazard radio	value
Sex
Female	236	1.93 (1.36-2.74)	0.00017	236	1.5 (1.06-2.14)	0.023
Male	544	1.59 (1.23-2.04)	0.00028	544	1.86 (1.5-2.3)
Stage
1	67	3.61 (1.35-9.65)	0.0062	67	2.02 (0.75-5.44)	0.16
2	140	2.39 (1.3-4.38)	0.0037	140	1.92 (1.03-3.56)	0.036
3	305	1.56 (0.17-2.09)	0.0023	305	1.66 (1.22-2.26)	0.001
4	148	0.76 (0.49-1.17)	0.21	148	0.71 (0.48-1.06)	0.091
Stage T
2	241	1.47 (0.93-2.3)	0.094	241	1.28 (0.82-2)	0.27
3	204	0.78 (0.54-1.13)	0.19	204	1.47 (0.97-2.22)	0.065
4	38	0.33 (0.1-1.11)	0.059	38	0.67 (0.28-1.59)	0.36
Stage N
0	74	2.03 (0.6-6.85)	0.24	74	1.75 (0.75-4.07)	0.19
1	225	2.63 (1.49-4.66)	0.00054	225	1.63 (1.07-2.48)	0.02
2	121	0.72 (0.45-1.15)	0.17	121	0.64 (0.41-1)	0.048
3	76	0.7 (0.37-1.31)	0.26	76	0.64 (0.38-1.1)	0.11
1+2+3	422	1.35 (1.01-1.8)	0.043	422	1.38 (1.3-1.54)	0.03
Stage M
0	444	1.3 (0.97-1.75)	0.082	444	1.32 (1-1.76)	0.053
1	56	0.77 (0.4-1.5)	0.44	56	0.37 (0.16-0.82)	0.011
Lauren classification
Intestinal	320	3.32 (1.5-3.59)	0.0001	320	1.74 (1.27-2.39)	0.00047
Diffuse	241	1.38 (0.97-1.97)	0.07	241	1.15 (0.81-1.62)	0.44
Differentiation
Poor	165	1.5 (0.98-2.3)	0.059	165	0.83 (0.55-1.23)	0.34
Moderate	67	0.57 (0.29-1.11)	0.096	67	0.56 (0.29-1.07)	0.075